Related Experiment Video
Updated: Feb 5, 2026

Harmonic Nanoparticles for Regenerative Research
Published on: May 1, 2014
Regulation of Regenerative Medicine Products
1cGMP Facilities, Center for Cell & Gene Therapy, Baylor College of Medicine, Houston, TX, USA. agee@bcm.edu.
Abstract:
Cellular therapies have moved to the forefront based upon promising results from clinical trials using both chimeric antigen receptor T lymphocytes to treat leukemia and other cell types to restore structure and function to tissues that have been damaged by disease or physical injury. The pace at which these treatments have evolved has posed a regulatory challenge to agencies, such as the Food and Drug Administration (FDA). This chapter describes how a specific regulatory strategy was developed and how it has evolved in response to the demand for these new therapies.
Related Concept Videos
Master Transcription Regulators
Negative Regulator Molecules
Regulated mRNA Transport
Epigenetic Regulation
GTPases and their Regulation
Large G-proteins,...
Microorganisms in Medicine and Therapeutics

